Cancer Systems Biology: a peek into the future of patient care?

Traditionally, scientific research has focused on studying individual events, such as single mutations, gene function, or the effect that mutating one protein has on a biological phenotype. A range of technologies is beginning to provide information that will enable a holistic view of how genomic and epigenetic aberrations in cancer cells can alter the homeostasis of signalling networks within these cells, between cancer cells and the local microenvironment, and at the organ and organism level. This process, termed Systems Biology, needs to be integrated with an iterative approach wherein hypotheses and predictions that arise from modelling are refined and constrained by experimental evaluation. Systems biology approaches will be vital for developing and implementing effective strategies to deliver personalized cancer therapy. Specifically, these approaches will be important to select those patients who are most likely to benefit from targeted therapies and for the development and implementation of rational combinatorial therapies. Systems biology can help to increase therapy efficacy or bypass the emergence of resistance, thus converting the current—often short term—effects of targeted therapies into durable responses, ultimately to improve patient quality of life and provide a cure.

[1]  Tyler J Moss,et al.  The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells , 2012, Molecular systems biology.

[2]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[3]  A. Edwards,et al.  Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines , 2011, Science Translational Medicine.

[4]  Paul A. Wiggins,et al.  Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state , 2011, Proceedings of the National Academy of Sciences.

[5]  Robert J. Gillies,et al.  Current Advances in Mathematical Modeling of Anti-Cancer Drug Penetration into Tumor Tissues , 2013, Front. Oncol..

[6]  S. Friend,et al.  Developing predictive molecular maps of human disease through community-based modeling , 2011, Nature Genetics.

[7]  Eytan Domany,et al.  A module of negative feedback regulators defines growth factor signaling , 2007, Nature Genetics.

[8]  S. Gygi,et al.  Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. , 2011, Molecular cell.

[9]  R. Cardiff,et al.  Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell of origin model for prostate cancer heterogeneity , 2013, Nature Cell Biology.

[10]  David E. Housman,et al.  Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines , 2013, PloS one.

[11]  D. Lauffenburger,et al.  Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress , 2012, Molecular systems biology.

[12]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[13]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[14]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[15]  David Haussler,et al.  Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling , 2011, Proceedings of the National Academy of Sciences.

[16]  Bahram Parvin,et al.  Linking Changes in Epithelial Morphogenesis to Cancer Mutations Using Computational Modeling , 2010, PLoS Comput. Biol..

[17]  P. Spellman,et al.  Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.

[18]  H. Ohtsuki,et al.  Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.

[19]  Joshua C. Gilbert,et al.  An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules , 2013, Cell.

[20]  Ken Ito,et al.  An Integrated Computational/Experimental Model of Lymphoma Growth , 2013, PLoS Comput. Biol..

[21]  J. Lowengrub,et al.  Multispecies model of cell lineages and feedback control in solid tumors. , 2012, Journal of theoretical biology.

[22]  Mechthild Krause,et al.  Three-dimensional cell growth confers radioresistance by chromatin density modification. , 2010, Cancer research.

[23]  J. Larkin,et al.  Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies , 2011, British Journal of Cancer.

[24]  Ernesto S. Nakayasu,et al.  Model-driven multi-omic data analysis elucidates metabolic immunomodulators of macrophage activation , 2012, Molecular systems biology.

[25]  Sean C. Bendall,et al.  Extracting a Cellular Hierarchy from High-dimensional Cytometry Data with SPADE , 2011, Nature Biotechnology.

[26]  G. Whitesides The origins and the future of microfluidics , 2006, Nature.

[27]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[28]  C. Sautès-Fridman,et al.  Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin , 2013, Clinical Cancer Research.

[29]  Gregory Stephanopoulos,et al.  The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4 , 2013, Cell.

[30]  P. Dijke,et al.  TGF-β signalling and its role in cancer progression and metastasis , 2012, Cancer and Metastasis Reviews.

[31]  C. Sander,et al.  Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.

[32]  G. Mills,et al.  Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer , 2012, Genome research.

[33]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[34]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[35]  Genee Y. Lee,et al.  The morphologies of breast cancer cell lines in three‐dimensional assays correlate with their profiles of gene expression , 2007, Molecular oncology.

[36]  M. Loda,et al.  A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer , 2013, Nature Genetics.

[37]  Daniel Gallahan,et al.  Systems biology: confronting the complexity of cancer. , 2011, Cancer research.

[38]  Alexander R A Anderson,et al.  Quantifying the Role of Angiogenesis in Malignant Progression of Gliomas: in Silico Modeling Integrates Imaging and Histology Nih Public Access Author Manuscript Introduction , 2011 .

[39]  Melissa H Wong,et al.  Tumor microenvironment complexity: emerging roles in cancer therapy. , 2012, Cancer research.

[40]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[41]  Ulrik B. Nielsen,et al.  Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 , 2012, Molecular Cancer Therapeutics.

[42]  Andrea Califano,et al.  Reverse‐engineering human regulatory networks , 2012, Wiley interdisciplinary reviews. Systems biology and medicine.

[43]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[44]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Chaplain,et al.  Paradoxical dependencies of tumor dormancy and progression on basic cell kinetics. , 2009, Cancer research.

[46]  E. Lengyel,et al.  Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra‐cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum , 2007, International journal of cancer.

[47]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[48]  D. Vitkup,et al.  Heterogeneity of tumor-induced gene expression changes in the human metabolic network , 2013, Nature Biotechnology.

[49]  Yiling Lu,et al.  Systematic analysis of genotype‐specific drug responses in cancer , 2012, International journal of cancer.

[50]  G. Mills,et al.  Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth , 2011, Nature Medicine.

[51]  C. Iacobuzio-Donahue,et al.  Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies , 2012, Cell.

[52]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[53]  A. Califano,et al.  STK38 is a critical upstream regulator of MYC’s oncogenic activity in human B-cell lymphoma , 2013, Oncogene.

[54]  Douglas A Lauffenburger,et al.  A mammalian functional-genetic approach to characterizing cancer therapeutics. , 2010, Nature chemical biology.

[55]  Chen-Hsiang Yeang,et al.  Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer , 2012, Proceedings of the National Academy of Sciences.

[56]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[57]  A. Trumpp,et al.  What does the concept of the stem cell niche really mean today? , 2012, BMC Biology.

[58]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[59]  Vittorio Cristini,et al.  Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements , 2013, Proceedings of the National Academy of Sciences.

[60]  K. Coombes,et al.  A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers , 2010, Clinical Proteomics.

[61]  Philip E. Bourne,et al.  Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..

[62]  Michael Peyton,et al.  Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.

[63]  P. Hahnfeldt,et al.  Cancer Stem Cells: A Minor Cancer Subpopulation that Redefines Global Cancer Features , 2013, Front. Oncol..

[64]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[65]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[66]  Xuerui Yang,et al.  An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma , 2011, Cell.

[67]  G. Collins The next generation. , 2006, Scientific American.

[68]  Mark A. J. Chaplain,et al.  Mathematical modeling of cancer cell invasion of tissue: biological insight from mathematical analysis and computational simulation , 2011, Journal of mathematical biology.

[69]  I. Mackenzie,et al.  Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. , 2011, Cancer research.

[70]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[71]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[72]  Maqc Consortium The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .

[73]  Mingsheng Zhang,et al.  Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. , 2011, Cancer research.

[74]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[75]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[76]  H. Woo,et al.  Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis , 2011, Proceedings of the National Academy of Sciences.

[77]  William C Reinhold,et al.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel , 2006, Molecular Cancer Therapeutics.

[78]  Luke A. Gilbert,et al.  Defining principles of combination drug mechanisms of action , 2012, Proceedings of the National Academy of Sciences.

[79]  Terence P. Speed,et al.  Bayesian Inference of Signaling Network Topology in a Cancer Cell Line , 2012, Bioinform..

[80]  Adam A. Margolin,et al.  Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer , 2013, Science Translational Medicine.

[81]  R. Bernards,et al.  Understanding resistance to targeted cancer drugs through loss of function genetic screens. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[82]  Thomas E Yankeelov,et al.  Clinically Relevant Modeling of Tumor Growth and Treatment Response , 2013, Science Translational Medicine.

[83]  Guy S. Salvesen,et al.  SnapShot: Caspases , 2011, Cell.

[84]  E. Danen,et al.  Cross-Talk between Integrins and Oncogenes Modulates Chemosensitivity , 2009, Molecular Pharmacology.

[85]  Thomas Streichert,et al.  Genome-Wide Gene Expression Analysis in Cancer Cells Reveals 3D Growth to Affect ECM and Processes Associated with Cell Adhesion but Not DNA Repair , 2012, PloS one.

[86]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[87]  Luay Nakhleh,et al.  Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling , 2011, Oncogene.

[88]  L. Chin,et al.  Making sense of cancer genomic data. , 2011, Genes & development.

[89]  A. Ashworth,et al.  Emerging therapeutic targets in endometrial cancer , 2011, Nature Reviews Clinical Oncology.

[90]  Lei Zhang,et al.  A reaction–diffusion mechanism influences cell lineage progression as a basis for formation, regeneration, and stability of intestinal crypts , 2012, BMC Systems Biology.

[91]  Karen Sachs,et al.  Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators , 2012, Nature Biotechnology.

[92]  Erhan Bilal,et al.  Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling , 2013, PLoS Comput. Biol..

[93]  V. Grantcharova,et al.  Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis , 2009, Science Signaling.

[94]  Daniel C Kirouac,et al.  Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors , 2013, Science Signaling.

[95]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[96]  Gavin MacBeath,et al.  Receptor Tyrosine Kinases Fall into Distinct Classes Based on Their Inferred Signaling Networks , 2013, Science Signaling.

[97]  G. Mills An emerging toolkit for targeted cancer therapies. , 2012, Genome research.

[98]  D. Lauffenburger,et al.  Networks Inferred from Biochemical Data Reveal Profound Differences in Toll-like Receptor and Inflammatory Signaling between Normal and Transformed Hepatocytes* , 2010, Molecular & Cellular Proteomics.

[99]  Q. Nie,et al.  Cell Lineages and the Logic of Proliferative Control , 2009, PLoS biology.

[100]  J. Rich,et al.  Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  W. Schiemann,et al.  Transforming growth factor-β and the hallmarks of cancer. , 2011, Cellular signalling.

[102]  Ernest Fraenkel,et al.  Linking Proteomic and Transcriptional Data through the Interactome and Epigenome Reveals a Map of Oncogene-induced Signaling , 2013, PLoS Comput. Biol..

[103]  John G. Albeck,et al.  Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. , 2013, Molecular cell.

[104]  Zhi Hu,et al.  Integrated analysis of breast cancer cell lines reveals unique signaling pathways , 2009, Genome Biology.

[105]  V. Quaranta,et al.  Fractional Proliferation: A method to deconvolve cell population dynamics from single-cell data , 2012, Nature Methods.